Thoraxcenter, Erasmus MC, Thoraxcenter, Gravendijkwal, 2303015 CE, Rotterdam, The Netherlands.
Expert Rev Med Devices. 2012 Jul;9(4):327-38. doi: 10.1586/erd.12.17. Epub 2012 Mar 16.
Everolimus-eluting ABSORB bioresorbable vascular scaffolds represent a novel approach that provides transient vessel support with drug-delivery capability without the long-term limitations of the metallic drug-eluting stents (DESs). The technology has the potential to overcome many of the safety concerns associated with metallic DESs and possibly even convey further clinical benefit. In particular the scaffold is designed for providing a short-term lumen support (up to 6-12 months) and for thereafter being completely bioresorbed, eliminating the permanent caging typical of the metallic DES. The first clinical studies testing this device in a small number of patients have shown very promising results with good clinical outcome up to 5 years' follow-up, highlighting important morphological and functional modifications at the scaffolded segment level, such as late lumen enlargement and recuperation of a normal vasoreactivity. A randomized trial, comparing ABSORB with the Xience Prime stent, will evaluate the efficacy and safety of this device in a wide population.
依维莫司洗脱 ABSORB 生物可吸收血管支架代表了一种新的方法，它提供了药物输送能力的暂时血管支持，而没有金属药物洗脱支架 (DESs) 的长期局限性。该技术有可能克服与金属 DESs 相关的许多安全问题，甚至可能带来进一步的临床获益。特别是该支架旨在提供短期管腔支持（最长 6-12 个月），然后完全生物吸收，消除金属 DES 典型的永久性笼状结构。在少数患者中进行的首批临床研究表明，该设备具有非常有前景的结果，在 5 年的随访中具有良好的临床结局，突出了支架节段水平的重要形态和功能改变，如晚期管腔扩大和恢复正常的血管反应性。一项比较 ABSORB 与 Xience Prime 支架的随机试验将评估该设备在广泛人群中的疗效和安全性。
